Thursday, October 31, 2013
Publication and contact
Colony-stimulating factor 1 receptor (CSF1R;
studies suggest the brain-penetrant CSF1R inhibitor BLZ945
could be used to treat glioblastoma multiforme (GBM). In a mouse model of platelet
derived growth factor B (PDGFB;
proneural GBM, BLZ945 inhibited tumor-associated macrophages and blocked
glioma growth, and it increased survival compared with vehicle. In mice with
proneural GBM xenografts, BLZ945 decreased tumor growth, tumor invasion and
expression of activated macrophage markers associated with tumor-promoting
functions compared with vehicle. Next steps could include using CSF1R
inhibitors in combination with glioma cell-directed therapies.
Institutes for BioMedical Research synthesized
BLZ945 and collaborated on this study. The development status of the compound
BioPharma Inc. has the small molecule CSF1R inhibitor ARRY-382
in Phase I testing to treat cancer.
Inc. has the humanized mAb AMG 820
in Phase I trials to treat cancer.
Lilly and Co. has the humanized mAb IMC-CS4
in Phase I testing to treat solid tumors.
has the humanized mAb RG7155
in Phase I trials to treat solid tumors.
Published online Oct. 31, 2013
Patent application filed by
AG and the Memorial
Sloan-Kettering Cancer Center; licensing status undisclosed
Pyonteck, S.M. et al.
Nat. Med.; published online Sept. 22, 2013;
Contact: Johanna A. Joyce, Memorial Sloan-Kettering Cancer
New York, N.Y.
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]